awmsg logo



evolocumab (Repatha®)


Reference No. 2866

Publication date:
27/07/2016


Appraisal information

evolocumab (Repatha®) 140 mg/ml solution for injection


Company: Amgen Ltd
BNF category: Cardiovascular system
NMG meeting date: 11/05/2016
AWMSG meeting date: 15/06/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1616
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Evolocumab (Repatha®) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download